<DOC>
	<DOCNO>NCT01141543</DOCNO>
	<brief_summary>The study conduct single center Phase I/II study evaluate safety administer Plerixafor administer part myeloablative preparative regimen ( Institutional Protocol : Fludarabine 50mg/m2/da x 4 day , Busulfan 3.2mg/kg/day x 4 day , TBI 400cGy divide fraction ) stem cell transplant recipient AML determine whether residual leukemic stem cell mobilize . Three patient enrol 4 sequential cohort . Patients first cohort receive 1 dose Plerixafor ( 240mcg/kg sc ) prior administration first dose Fludarabine Busulfan . If tolerate plan escalate number Plerixafor dose subsequent cohort 2 . 3. 4 administer respective 2nd , 3rd , 4th dose chemotherapy .</brief_summary>
	<brief_title>Feasibility Efficiency Study Leukemic Cell Mobilization With Plerixafor Injection</brief_title>
	<detailed_description>The study conduct single center Phase I/II study evaluate safety administer PLERIXAFOR part myeloablative preparative regimen ( Institutional Protocol : FBT ( 400 ) - FLUDARABINE 50mg/m2/d x 4 day , BUSULFAN 3.2mg/kg/day x 4 day , TBI 400cGy 2 fraction ) stem cell transplant recipient Acute Myeloid Leukemia ( AML ) determine whether residual leukemic stem cell mobilize . Three patient enrol 4 sequential cohort . Patients first cohort receive 1 dose ( 240mcg/kg SC ) PLERIXAFOR ( MOZOBIL , formerly know AMD3100 ) prior administration first dose FLUDARABINE BUSULFAN It plan escalate number PLERIXAFOR dose subsequent cohort 2 . 3. 4 administer respective 2nd , 3rd , 4th dos chemotherapy . As primary endpoint study establish toxicity combine administration PLERIXAFOR preparative regimen dose level . Secondary endpoint include quantification CXCR4 positive cell candidate leukemic disease propagate cell administration PLERIXAFOR . Mobilized cell examine ability undergo apoptosis . Clinical parameter include SAE , OS LFS part evaluation . The comparison cell population peripheral blood PLERIXAFOR may facilitate good definition minimal residual disease patient deem morphologically complete remission . The assessment completion preparative regimen provide measurement minimal residual disease prior transplant . The assessment residual leukemic cell respect apoptosis define responsiveness administration FLUDARABINE BUSULFAN . The obtained information facilitate development new platform optimize preparation patient transplant . Eg . Insufficient mobilization leukemic cell may address future study combine mobilization strategy . Similarly , cell show apoptosis resistant one may able include apoptosis induce small molecule .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Patients AML remission . Availability suitably match related unrelated donor Age 1860 year Eligibility myeloablative transplant use Institutional protocol RFBT ( 400 ) CSMF preparative regimen related donor UFBT ( 400 ) CP ( 30 ) CS unrelated donor . Eligible subject illiterate offer participation study Exclusion criterion : Patients age 61years old Patients eligible preparative regimen RFBT ( 400 ) CSMF UFBT ( 400 ) CP ( 30 ) CS Pregnant lactate female Creatinine . &gt; 2x normal Bilirubin , AST , ALT &gt; 2x normal MUGA &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Plerixafor injection</keyword>
</DOC>